Merck announces positive results from phase 3 KEYNOTE-966 trial of Keytruda in combo with chemotherapy to treat advanced or unresectable biliary tract cancer

Merck, known as MSD outside of the United States and Canada, announced positive results from the phase 3 KEYNOTE-966 trial. In the final analysis of this trial, Keytruda, Merck